Study of Albumin Function in Hemodialysis Patients
Part of Infections clinical trials.
This study looks at how well a protein called albumin works in people who are on regular hemodialysis (dialysis for kidney failure). It aims to understand kidney-related health better, and may help improve future care for dialysis patients.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You need to have been on hemodialysis (dialysis for kidney failure) at least 3 times a week for at least 3 months, with the same routine.
- You cannot have any liver disease, such as cirrhosis or liver failure.
- You cannot have received an infusion of human albumin (a protein) in the last 3 months, for example for removing fluid from the belly.
- You cannot have a serious infection or active cancer right now.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether giving albumin (a blood protein) in a personalized dose works better than a standard fixed dose for people with cirrhosis and sepsis-related acute kidney injury. The goal is to find a safer and more effective way to protect kidney function.
This study tests whether giving a common fluid (albumin) early can help protect the kidneys in people with advanced liver disease who have a sudden kidney injury. It aims to see if this simple treatment can improve recovery and prevent the need for dialysis.
This trial tests if giving a medicine called albumin through a vein can help prevent kidney function from getting worse in people hospitalized with worsening heart failure and liver problems. It may be an option if other treatments haven't worked.
This study tests a long-term, high-flow hemoadsorption therapy for people on maintenance hemodialysis. It aims to see if the treatment can improve outcomes for those with uremia (built-up waste in the blood).
This study tests a new way to do hemodialysis that might remove certain waste products (called protein-bound uremic toxins) more effectively than standard dialysis. It could help people on long-term dialysis feel better and have fewer complications.
This study is looking at whether changes in a protein called albumin can help find liver disease earlier. It is for people who have some liver scarring but no serious complications.
Hear when a new Albumin trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.